New Alzheimer's vaccine shows promise in Early-Stage trial
Disease control
Completed
This study tested a vaccine called ABvac40 in 134 people with very mild Alzheimer's or mild cognitive impairment. The vaccine aims to train the immune system to attack a specific protein (Aβ40) linked to Alzheimer's. The main goal was to check safety and immune response over 24 m…
Phase: PHASE2 • Sponsor: Araclon Biotech S.L. • Aim: Disease control
Last updated May 17, 2026 02:38 UTC